Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Yao JC, et al. Among authors: kvols lk. J Clin Oncol. 2010 Jan 1;28(1):69-76. doi: 10.1200/JCO.2009.24.2669. Epub 2009 Nov 23. J Clin Oncol. 2010. PMID: 19933912 Free PMC article. Clinical Trial.
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Kvols LK, Oberg KE, O'Dorisio TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B. Kvols LK, et al. Endocr Relat Cancer. 2012 Sep 14;19(5):657-66. doi: 10.1530/ERC-11-0367. Print 2012 Oct. Endocr Relat Cancer. 2012. PMID: 22807497 Clinical Trial.
Neuroendocrine tumors.
Clark OH, Ajani J, Benson AB 3rd, Byrd D, Doherty GM, Engstrom PF, Ettinger DS, Gibbs JF, Heslin MJ, Kandeel F, Kessinger A, Kulke MH, Kvols L, Nemcek AA Jr, Olson JA Jr, Ratliff TW, Saltz L, Schteingart DE, Shah MH, Shibata S; National Comprehensive Cancer Network. Clark OH, et al. J Natl Compr Canc Netw. 2006 Feb;4(2):102-38. doi: 10.6004/jnccn.2006.0013. J Natl Compr Canc Netw. 2006. PMID: 16451769 Review. No abstract available.
A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.
Strosberg JR, Chan JA, Ryan DP, Meyerhardt JA, Fuchs CS, Abrams T, Regan E, Brady R, Weber J, Campos T, Kvols LK, Kulke MH. Strosberg JR, et al. Among authors: kvols lk. Endocr Relat Cancer. 2013 May 21;20(3):383-90. doi: 10.1530/ERC-12-0390. Print 2013 Jun. Endocr Relat Cancer. 2013. PMID: 23572164 Free PMC article. Clinical Trial.
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A. Kulke MH, et al. Endocr Relat Cancer. 2014 Oct;21(5):705-14. doi: 10.1530/ERC-14-0173. Epub 2014 Jul 10. Endocr Relat Cancer. 2014. PMID: 25012985 Free PMC article. Clinical Trial.
Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, Erion JL, O'Dorisio TM, Kvols LK, Simon J, Wolfangel R, Camp A, Krenning EP, Mojtahedi A. Delpassand ES, et al. Among authors: kvols lk. Pancreas. 2014 May;43(4):518-25. doi: 10.1097/MPA.0000000000000113. Pancreas. 2014. PMID: 24632546 Clinical Trial.
212 results